Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington's disease

•  Heart disease has been attributed as a major cause of death in patients with Huntington's disease (HD). While little is known about cardiac complication(s) in HD, dysfunction of the autonomic nervous system (ANS) may play a role. •  Using a mouse model of HD, we demonstrated that even from an early HD phase, there was enhanced sympathetic and parasympathetic nervous activities, leading to an unstable heart beat, various arrhythmias and, ultimately, sudden arrhythmic death. •  Greater numbers of active neurons were found in brain regions important for autonomic regulation in HD mice, suggesting a centrally mediated mechanism that was underlying the ANS‐cardiac dysfunction. •  Our findings provide insight into a likely neurocardiac cause of death in HD, and warrant further clinical investigation.

[1]  M. Mattson,et al.  Aberrant heart rate and brainstem brain-derived neurotrophic factor (BDNF) signaling in a mouse model of Huntington's disease , 2012, Neurobiology of Aging.

[2]  C. Colwell,et al.  Baroreceptor reflex dysfunction in the BACHD mouse model of Huntington’s disease. , 2011, PLoS currents.

[3]  C. Colwell,et al.  Dysfunctions in circadian behavior and physiology in mouse models of Huntington's disease , 2011, Experimental Neurology.

[4]  G. Head,et al.  Role of the medial amygdala in mediating responses to aversive stimuli leading to hypertension , 2011, Clinical and experimental pharmacology & physiology.

[5]  G. Bates,et al.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. , 2011, The Journal of clinical investigation.

[6]  G. Head,et al.  Cardiovascular responses to aversive and nonaversive stressors in Schlager genetically hypertensive mice. , 2010, American journal of hypertension.

[7]  J. Marinus,et al.  Autonomic symptoms in patients and pre‐manifest mutation carriers of Huntington’s disease , 2010, European journal of neurology.

[8]  J. Coote,et al.  Vagus nerve stimulation inhibits the increase in Ca2+ transient and left ventricular force caused by sympathetic nerve stimulation but has no direct effects alone – epicardial Ca2+ fluorescence studies using fura‐2 AM in the isolated innervated beating rabbit heart , 2010, Experimental physiology.

[9]  T. Walther,et al.  Role of Angiotensin II Type 1A Receptors in Cardiovascular Reactivity and Neuronal Activation After Aversive Stress in Mice , 2009, Hypertension.

[10]  V. Silani,et al.  Huntington's disease: The current state of research with peripheral tissues , 2009, Experimental Neurology.

[11]  A. Dart,et al.  Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. , 2009, The American journal of pathology.

[12]  P. Brundin,et al.  Beyond the brain: widespread pathology in Huntington's disease , 2009, The Lancet Neurology.

[13]  S. Leurgans,et al.  Daytime somnolence and nocturnal sleep disturbances in Huntington disease. , 2009, Parkinsonism & related disorders.

[14]  H. Pijl,et al.  Delayed onset of the diurnal melatonin rise in patients with Huntington’s disease , 2009, Journal of Neurology.

[15]  A. Rego,et al.  The R6 lines of transgenic mice: A model for screening new therapies for Huntington's disease , 2009, Brain Research Reviews.

[16]  A. Hannan,et al.  Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease. , 2009, Human molecular genetics.

[17]  R. Leung,et al.  Sleep-disordered breathing: autonomic mechanisms and arrhythmias. , 2009, Progress in cardiovascular diseases.

[18]  Hongmei Li,et al.  Neural Mechanisms of Paroxysmal Atrial Fibrillation and Paroxysmal Atrial Tachycardia in Ambulatory Canines , 2008, Circulation.

[19]  Brian Olshansky,et al.  Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. , 2008, Circulation.

[20]  Marcus W. Agelink,et al.  Cardiovagal modulation upon postural change is altered in Huntington’s disease , 2008, European journal of neurology.

[21]  J. Robbins,et al.  Cardiomyocyte Expression of a Polyglutamine Preamyloid Oligomer Causes Heart Failure , 2008, Circulation.

[22]  J. Rumberger Assessment of Cardiac Function , 2008 .

[23]  Robert S. Decker,et al.  Neural substrate for atrial fibrillation: implications for targeted parasympathetic blockade in the posterior left atrium. , 2008, American journal of physiology. Heart and circulatory physiology.

[24]  G. Head,et al.  Fos-Related Antigen Immunoreactivity After Acute and Chronic Angiotensin II–Induced Hypertension in the Rabbit Brain , 2007, Hypertension.

[25]  Peng-Sheng Chen,et al.  Autonomic nerve activity and atrial fibrillation. , 2007, Heart rhythm.

[26]  Andrew D. Steele,et al.  The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases , 2007, Proceedings of the National Academy of Sciences.

[27]  K. Hoyt,et al.  Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease , 2007, Neurobiology of Disease.

[28]  M. Fishbein,et al.  New Perspectives on the Role of Autonomic Nervous System in the Genesis of Arrhythmias , 2007, Journal of cardiovascular electrophysiology.

[29]  R. Graham,et al.  Transgenic alpha1A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival. , 2006, Cardiovascular research.

[30]  G. Billman A comprehensive review and analysis of 25 years of data from an in vivo canine model of sudden cardiac death: implications for future anti-arrhythmic drug development. , 2006, Pharmacology & therapeutics.

[31]  G. Bates History of genetic disease: The molecular genetics of Huntington disease — a history , 2005, Nature Reviews Genetics.

[32]  V. Shusterman,et al.  Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha}. , 2005, American journal of physiology. Heart and circulatory physiology.

[33]  R. Barker,et al.  Disintegration of the Sleep-Wake Cycle and Circadian Timing in Huntington's Disease , 2005, The Journal of Neuroscience.

[34]  B. Peterlin,et al.  Early sympathetic hyperactivity in Huntington's disease , 2004, European journal of neurology.

[35]  Geoffrey A Head,et al.  Non-symmetrical double-logistic analysis of 24-h blood pressure recordings in normotensive and hypertensive rats , 2004, Journal of hypertension.

[36]  A. Allen,et al.  Descending vasomotor pathways from the dorsomedial hypothalamic nucleus: role of medullary raphe and RVLM. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[37]  M. Capecchi,et al.  Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. , 2004, The American journal of pathology.

[38]  L. Burger,et al.  Bradycardia and second-degree AV block: an expression of the dominance of cholinergic activity in the rigid form of Huntington's disease , 2004, Journal of Neurology.

[39]  A. Dart,et al.  Assessment of Cardiac Function by Echocardiography in Conscious and Anesthetized Mice: Importance of the Autonomic Nervous System and Disease State , 2003, Journal of cardiovascular pharmacology.

[40]  H. Przuntek,et al.  Autonomic nervous system function in Huntington's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[41]  G. Jennings,et al.  Age-dependent cardiomyopathy and heart failure phenotype in mice overexpressing beta(2)-adrenergic receptors in the heart. , 2000, Cardiovascular research.

[42]  E. Woodcock,et al.  Increased collagen content reduces the risk of post-infarct cardiac rupture in mice that overexpress β2-adrenergic, receptors in the heart , 2000 .

[43]  R Lazzara,et al.  Catheter Ablation of Cardiac Autonomic Nerves for Prevention of Vagal Atrial Fibrillation , 2000, Circulation.

[44]  J. Romano,et al.  Sympathetic skin response and heart rate variability in patients with Huntington disease. , 1999, Archives of neurology.

[45]  A. Dart,et al.  Sympathetic activation triggers ventricular arrhythmias in rat heart with chronic infarction and failure. , 1999, Cardiovascular research.

[46]  J Ross,et al.  Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. , 1999, The Journal of clinical investigation.

[47]  M. Lohse,et al.  Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[48]  I. Jonsdottir,et al.  Influence of voluntary exercise on hypothalamic norepinephrine. , 1998, Journal of applied physiology.

[49]  G. Mitchell,et al.  Measurement of heart rate and Q-T interval in the conscious mouse. , 1998, American journal of physiology. Heart and circulatory physiology.

[50]  S. W. Davies,et al.  Transgenic models of Huntington's disease. , 1999, Human molecular genetics.

[51]  S. W. Davies,et al.  Transgenic models of Huntington's disease. Hum Mol Genet 6:1633-1637 , 1997 .

[52]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[53]  Y. Furukawa,et al.  Parasympathetic inhibition of sympathetic effects on sinus rate in anesthetized dogs. , 1996, The American journal of physiology.

[54]  A. Quyyumi,et al.  Cardiac sympathetic nerve function in congestive heart failure. , 1996, Circulation.

[55]  Y. Hirooka,et al.  Use of c-fos functional mapping to identify the central baroreceptor reflex pathway: advantages and limitations. , 1995, Clinical and experimental hypertension.

[56]  R. Dampney,et al.  Functional organization of central pathways regulating the cardiovascular system. , 1994, Physiological reviews.

[57]  G. Jennings,et al.  Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. , 1994, Journal of the American College of Cardiology.

[58]  M. Kashiki,et al.  Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. , 1993, Circulation.

[59]  I. Meredith,et al.  Cardiac Sympathetic Nervous Activit in Congestive Heart Failure Evidence for Increased Neuronal Norepinephrine Release and Preserved Neuronal Uptake , 1993, Circulation.

[60]  K. Fenger,et al.  Causes of death in patients with Huntington's disease and in unaffected first degree relatives. , 1992, Journal of medical genetics.

[61]  P. Schwartz,et al.  Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. , 1992, Circulation.

[62]  S. Sakamoto,et al.  Chronic beta-adrenoceptor blockade prevents the development of beta-adrenergic subsensitivity in experimental right-sided congestive heart failure in dogs. , 1991, Circulation.

[63]  D. Lanska,et al.  Huntington's disease mortality in the United States , 1988, Neurology.

[64]  J. G. van Dijk,et al.  Autonomic nervous function in Huntington's disease. , 1988, Archives of neurology.

[65]  A. Kadish,et al.  Accentuated antagonism between beta-adrenergic and vagal effects on ventricular refractoriness in humans. , 1988, Circulation.

[66]  E. Chiu,et al.  Causes of death in Huntington's Disease , 1982, The Medical journal of Australia.

[67]  J. Ross,et al.  Assessment of Cardiac Function , 1969 .